Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MTCR

Metacrine (MTCR) Stock Price, News & Analysis

Metacrine logo

About Metacrine Stock (NASDAQ:MTCR)

Advanced Chart

Key Stats

Today's Range
$0.58
$0.59
50-Day Range
$0.55
$0.59
52-Week Range
$0.30
$0.59
Volume
83,889 shs
Average Volume
225,834 shs
Market Capitalization
$24.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Receive MTCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter.

MTCR Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Headlines

MTCR Stock Analysis - Frequently Asked Questions

Metacrine, Inc. (NASDAQ:MTCR) posted its quarterly earnings data on Thursday, May, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.06.

Metacrine (MTCR) raised $84 million in an initial public offering (IPO) on Wednesday, September 16th 2020. The company issued 6,500,000 shares at a price of $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metacrine investors own include Outlook Therapeutics (OTLK), Plug Power (PLUG), Advanced Micro Devices (AMD), Salesforce (CRM), Fisker (FSR), Micron Technology (MU) and 9 Meters Biopharma (NMTR).

Company Calendar

Last Earnings
5/13/2021
Today
5/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MTCR
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.21 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.36 per share
Price / Book
0.43

Miscellaneous

Free Float
36,695,000
Market Cap
$24.75 million
Optionable
Not Optionable
Beta
-0.73
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:MTCR) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners